Genentech to buy breast cancer specialist Seragon


Roche subsidiary Genentech has agreed to pay $725 million (£422 million) up front, plus up to $1 billion in milestone payments, for fledgling biotech firm Seragon Pharmaceuticals. The deal gives Genentech access to Seragon’s pipeline of investigational breast cancer therapies that work by destroying oestrogen receptors on the surface of cancer cells.

Certain breast cancers rely on the hormone oestrogen to grow and spread. Seragon’s drug candidates are designed to eliminate the tumours’ ability to develop resistance to drugs that block oestrogen receptors (including tamoxifen) or interfere with its production (such as aromatase inhibitors).

Seragon was only formed as a company in 2013. It was spun out of Aragon Pharmaceuticals when that company sold its hormone-based prostate cancer treatment pipeline to Johnson and Johnson.


Related Content

J&J buys Aragon’s prostate cancer arm

22 August 2013 Business

news image

Hormone cancer specialist spins out other programmes before sale

Targeting breast cancer

28 March 2014 Premium contentFeature

news image

Tamoxifen has been treating breast cancer for 40 years, but few would have predicted how much this drug would contribute to s...

Most Commented

Countries ink Paris climate change agreement

27 April 2016 News and Analysis

news image

Nearly 200 countries signed the global climate treaty that aims to limit temperature rises to ‘well below’ 2°C

Shadow of Chernobyl

26 April 2016 Critical Point

news image

Mark Peplow takes the long view on the cost of nuclear power